Nanoviricides Stock Price, News & Analysis

NanoViricides announces that Dr. Anil R. Diwan, President and Executive Chairman, will present at the PODD Conference on October 28, 2024, at 3:45 PM. The conference will take place at the Westin Boston Seaport District, MA. Dr. Diwan's talk, titled 'Revolutionizing Antiviral Treatments, Phase 2-Ready, Orally Available Nanomedicines That Can Deliver Difficult APIs And Improve PK', will focus on the nanoviricides platform technology and its achievements.

Key points include the broad-spectrum drug candidate NV-387, which has completed Phase 1 trials with excellent safety and efficacy against various viruses, including RSV, Influenza A/H3N2, coronavirus, and poxvirus. NV-387 is orally available and has shown superior results compared to existing treatments like oseltamivir, peramivir, and remdesivir in animal models. Dr. Diwan will also discuss the platform's potential to revolutionize drug delivery, enabling oral availability and protection from metabolism for difficult drugs.

NanoViricides, Inc. (NYSE American:NNVC) announces that its President, Dr. Anil R. Diwan, was interviewed in a PODD Conference podcast. Dr. Diwan discussed the company's nanoviricides technology platform and its broad-spectrum antiviral clinical drug candidate NV-387. He explained how NV-387 could revolutionize viral infection treatment, similar to penicillin's impact on bacterial infections.

Dr. Diwan highlighted NV-387's potential to resist viral escape and the company's multiple Phase II clinical trial strategies. He also elaborated on how the nanoviricide platform can aid other pharmaceutical innovators in developing effective drugs. The technology enables oral drug delivery of difficult-to-dose APIs, protects APIs from bodily metabolism, and allows for targeted drug delivery to specific cells or pathogens.

NanoViricides (NYSE American:NNVC) announces that its President, Dr. Anil R. Diwan, will present at the Global AMR Summit 2024 on October 9, 2024, in Cambridge, MA. Dr. Diwan will discuss the company's 'Trojan Horse' Platform Technology to combat antimicrobial resistance (AMR).

The technology enables delivery of 'war-heads' directly onto pathogens, potentially reducing toxicity and improving pharmacokinetics. NanoViricides' lead drug, NV-387, has completed Phase 1a/1b trials with no reported adverse events. It has shown strong antiviral activity against multiple virus families, including Coronaviruses, RSV, and Influenza A.

NV-387 could be the first single drug to treat all 'tripledemic' viral infections. The company is also developing 'dual-action' nanoviricides to potentially cure viral infections by blocking the complete Virus Life Cycle.

NanoViricides has filed its Annual Report for the fiscal year ending June 30, 2024. As of June 30, 2024, the company reported approximately $4.97 million in cash and equivalents, $7.5 million in net property and equipment, and $1.36 million in total current liabilities. The company utilized $6.31 million for operating activities, including Phase Ia/Ib clinical trials of NV-387. NanoViricides raised $3.12 million through an At-the-Market offering and an additional $1.53 million subsequently, increasing its available cash to approximately $9.5 million. Despite this, the company expressed substantial doubt about its ability to continue operations through September 2025 without additional funding. NV-387, a broad-spectrum antiviral, has shown promise in preclinical trials and is advancing to Phase II clinical trials for RSV and MPOX. The company is exploring non-dilutive funding and partnerships to support its objectives.

NanoViricides has signed a Memorandum of Understanding (MoU) with TheraCour Pharma, granting it a right of first refusal (ROFR) for all antiviral drug developments. This agreement, made on September 23, 2024, includes intellectual property rights for developing treatments against any viral infections.

The company's lead drug, NV-387, has shown promising results in animal studies against various viruses and is set to enter Phase II clinical trials for diseases like RSV, Influenza, Bird Flu, COVID, and MPOX/Smallpox. Additionally, the company has developed 'Trojan Horse' drugs that can target multiple stages of a virus's lifecycle.

This MoU allows NanoViricides to rapidly develop new antiviral drugs, even for unforeseen viruses, and negotiate licenses for specific antiviral fields. The nanoviricide technology aims to revolutionize antiviral treatments by mimicking host cells to destabilize viruses.

NanoViricides (NYSE:NNVC) is investigating the use of its drug candidate NV-387 to treat MPOX under the WHO MEURI protocol, following the recent MPOX outbreak declaration. Key points:

1. NV-387 completed Phase I trials with no adverse events reported.
2. It showed strong survival improvement in animal studies, matching the approved drug tecovirimat.
3. NV-387 was found superior or equivalent to existing drugs for RSV, Influenza, and COVID in non-clinical trials.
4. The current MPOX epidemic is caused by Clade 1/1b, which is more severe than the 2022 Clade 2 outbreak.
5. NV-387 acts via 'Re-Infection Inhibition', blocking virus cell infection.

The company believes NV-387 could be revolutionary for viral infection treatment if proven effective in human trials.

NanoViricides is progressing towards a Phase II clinical trial of its drug candidate NV-387, aimed at treating multiple viral infections including RSV, COVID, and Influenza. Dr. Anil Diwan is collaborating with experts to develop a trial plan and protocol. NV-387 has demonstrated strong effectiveness in animal studies and could potentially become a first-line treatment for respiratory viral infections, eliminating the need for testing virus types before treatment.

The estimated market size for these infections is over $8 billion in 2024, expected to grow to $12 billion by 2027. The Phase II trial will assess NV-387's effectiveness against multiple viruses in a single study, aiming to reduce costs and enhance return on investment. NV-387 recently completed a Phase I trial, showing good tolerability. The company envisions a new paradigm in treating viral infections, similar to broad-spectrum antibiotics for bacteria.

NanoViricides (NYSE:NNVC) provides an update on its clinical program for NV-387, a broad-spectrum antiviral drug. Key points:

• NV-387 mimics sulfated-proteoglycan features used by over 90% of pathogenic human viruses to infect cells
• Showed superiority or equivalence to existing drugs in animal trials against influenza, COVID, RSV, and orthopoxviruses
• Potential market size of $8 billion in 2024, growing to $12 billion in three years for influenza, RSV, and COVID alone
• Company completing database audit of Phase 1a/1b trial and preparing for Phase II trials
• Developing novel adaptive clinical trial design to evaluate effectiveness against multiple respiratory viruses
• Initiating outreach for big pharma collaborations to speed up programs and provide financing

NanoViricides, Inc. (NYSE American: NNVC) is developing NV-387, a broad-spectrum antiviral drug candidate showing promise against multiple viruses, including COVID-19, RSV, and influenza. The company recently completed a Phase 1 safety study for NV-387, with results expected in the second half of 2024. A Phase 2 clinical trial for RSV is being planned.

Key highlights:

• NV-387 demonstrated 180% improvement in survival compared to Remdesivir's 50% in animal studies
• Oral and injectable formulations developed
• Showed excellent safety and tolerability in Phase 1 human trials
• Potential to address limitations of current COVID-19 treatments
• Broad spectrum activity could represent a new paradigm in viral therapy